Fine analysis of spontaneous MAGE-C1/CT7 - Specific immunity in melanoma patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 34, 2010, Pages 15187-15192

  Nuber, Natko ^a   Curioni Fontecedro, Alessandra ^a   Mattera, Claudia ^a   Soldinib, Davide ^a   Tiercyc, Jean Marie ^b   Von Boehmera, Lotta ^a   Mochb, Holger ^a   Dummerd, Reinhard ^c   Knutha, Alexander ^a   Van Den Broeka, Maries ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cancer testis antigens; T cell response

Indexed keywords

ANTIGEN; ANTIGEN CT7; ANTIGEN MAGE C1; ANTINEOPLASTIC AGENT; CANCER VACCINE; CD45RA ANTIGEN; EPITOPE; IMMUNOMODULATING AGENT; PERFORIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CT7 ANTIGEN, HUMAN; MAGEC1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FINITE ELEMENT ANALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; RESTRICTION SITE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR LOCALIZATION; VACCINATION; AMINO ACID SEQUENCE; EPITOPE MAPPING; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; METASTASIS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNOLOGIC MEMORY; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 77956990082     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1002155107     Document Type: Article

References (45)

1. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13: 1-27.
2. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148.
3. Galon J, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964.
4. Moschos SJ, et al. (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24: 3164-3171.
5. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208.
6. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625.
7. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 4:1.
8. Knuth A, Danowski B, Oettgen HF, Old LJ (1984) T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci USA 81:3511-3515. (Pubitemid 14122704)
9. van der Bruggen P, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
10. Jäger E, et al. (2006) Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103:14453-14458.
11. Marchand M, et al. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230.
12. Valmori D, et al. (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104:8947-8952.
13. Kruit WH, et al. (2005) Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117:596-604.
14. Atanackovic D, et al. (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105:1650-1655. (Pubitemid 351346569)
15. Gnjatic S, et al. (2006) NY-ESO-1: Review of an immunogenic tumor antigen. Adv Cancer Res 95:1-30. (Pubitemid 44088423)
16. Jäger E, Jäger D, Knuth A (1999) CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev 18:143-150. (Pubitemid 29411098)
17. Jäger E, et al. (1996) Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470-476. (Pubitemid 26178170)
18. Kessler JH, Melief CJ (2007) Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21:1859-1874. (Pubitemid 47299958)
19. Bajetta E, et al. (2002) Metastatic melanoma: Chemotherapy. Semin Oncol 29: 427-445.
20. Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res 19:21-34. (Pubitemid 30305516)
21. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH (1991) Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214:491-499, discussion 499-501.
22. Kirkwood JM, et al. (2008) Next generation of immunotherapy for melanoma. J Clin Oncol 26:3445-3455.
23. Fang L, Lonsdorf AS, Hwang ST (2008) Immunotherapy for advanced melanoma. J Invest Dermatol 128:2596-2605.
24. Lee CC, Faries MB, Wanek LA, Morton DL (2009) Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 27:3489-3495.
25. Mihm MC, Jr, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43-47.
26. Lucas S, et al. (1998) Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 58:743-752. (Pubitemid 28099487)
27. Chen YT, et al. (1998) Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95: 6919-6923.
28. Dhodapkar MV, et al. (2003) Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 3:9.
29. Häffner AC, et al. (2002) Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer 97:668-670. (Pubitemid 34087808)
30. Jungbluth AA, et al. (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99:839-845.
31. Lendvai N, et al. (2010) Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun 10:4.
32. Barrow C, et al. (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764-771. (Pubitemid 43259856)
33. Lüftl M, Schuler G, Jungbluth AA (2004) Melanoma or not? Cancer testis antigens may help. Br J Dermatol 151:1213-1218. (Pubitemid 40030169)
34. Curioni-Fontecedro A, et al. (2008) MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia 22:1646-1648.
35. Jäger E, et al. (1999) Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events. Int J Cancer 84:506-510.
36. Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic selftolerance and negative control of immune responses. Annu Rev Immunol 22:531-562.
37. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218.
38. Duvall MG, et al. (2008) Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38:350-363.
39. Quezada SA, et al. (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207:637-650.
40. Xie Y, et al. (2010) Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207:651-667.
41. Balch CM, et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648.
42. Pawelec G, Marsh SG (2006) ESTDAB: A collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol Immunother 55: 623-627. (Pubitemid 43312157)
43. Knights AJ, et al. (2009) Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother 58:325-338.
44. Walton SM, et al. (2006) Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol 177: 8212-8218.
45. Tosato G, Cohen JI (2007) Generation of Epstein-Barr virus (EBV)-immortalized B cell lines. Curr Protoc Immunol, 10.1002/0471142735. im0722s76.